Summary
HormoCaps will help us demonstrate the viability as a commercial product of a dual-action drug delivery system which synergizes its own biological effect and that of the encapsulated bioactive molecule for the oral delivery of peptides. This would represent an alternative to current oral incretin-based treatments for gastrointestinal metabolic disorders. In HormoCaps, we will (i) demonstrate the translational feasibility of our strategy; (ii) evaluate the capacity of the formulation to simultaneously stimulate the secretion of hormones that are present at different concentrations at distinct regions of the gastrointestinal mucosa; and (iii) consolidate our results towards a licensing plan to guide the commercialization of our formulation.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101158056 |
| Start date: | 01-07-2024 |
| End date: | 31-12-2025 |
| Total budget - Public funding: | - 150 000,00 Euro |
Cordis data
Original description
HormoCaps will help us demonstrate the viability as a commercial product of a dual-action drug delivery system which synergizes its own biological effect and that of the encapsulated bioactive molecule for the oral delivery of peptides. This would represent an alternative to current oral incretin-based treatments for gastrointestinal metabolic disorders. In HormoCaps, we will (i) demonstrate the translational feasibility of our strategy; (ii) evaluate the capacity of the formulation to simultaneously stimulate the secretion of hormones that are present at different concentrations at distinct regions of the gastrointestinal mucosa; and (iii) consolidate our results towards a licensing plan to guide the commercialization of our formulation.Status
SIGNEDCall topic
ERC-2023-POCUpdate Date
12-03-2024
Images
No images available.
Geographical location(s)
